Trevi Therapeutics Inc (NASDAQ:TRVI)
| 2.44 Delayed Data As of 3:59pm ET |  +0.28 / +12.96%Today’s Change | 1.43 Today|||52-Week Range 4.68 | +26.42% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $135.8M |
Company Description
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
Contact Information
Trevi Therapeutics, Inc. 195 Church Street New Haven Connecticut 06510 |
Employees
Shareholders
| Other institutional | 38.11% |
| Mutual fund holders | 3.57% |
| Individual stakeholders | 20.77% |
Top Executives
| Jennifer L. Good | President, Chief Executive Officer & Director |
| Lisa Delfini | Chief Financial Officer |
| Thomas R. Sciascia | Chief Science Officer |
| Danine Summers | Vice President-Medical Affairs |
| David J. Clark | Chief Medical Officer |
